The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Average US review times match absolute approval numbers in remaining unaffected by the Covid pandemic.
The group is taking a subcutaneous formulation of efgartigimod to regulators, but is keeping quiet about price.
Biomarkers and precise targeting could help the anti-TGF-β1 antibody SRK-181 succeed where bintrafusp failed, the group hopes.
Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
Kodiak, Biomarin and Argenx prepare for clinical catalysts.
2022 kicks off with key FDA decisions for Roche, Novartis and Pfizer, while Astrazeneca hopes to extend Lynparza even further.